Skip to main content

Table 7 The main studies describing the effectiveness/limitations of LPS adsorbers

From: Extracorporeal techniques for the treatment of critically ill patients with sepsis beyond conventional blood purification therapy: the promises and the pitfalls

  Yaroustovsky et al. 2009 [60] Ala-Kokko et al. 2011 [61] Adamik et al. 2015 [62]
Study design Observational Case series with matched controls Observational
Study population (n) 13 Gram-negative sepsis 24 septic shock patients and endotoxaemia. 62 septic shock and suspected Gram-negative
EAA assessment More than 0.3 considered endotoxaemia EA [0.70 EA units (0.66–0.77)].
Prescribed dose Two sessions with a maximum duration of 120 min/patient
Alteco adsorber (n = 6) and toraymyxin (n = 7)
2-h LPS HP LPS elimination + ST vs ST
1–2 sessions
Timing Within 36 h Within 24 h
Survival No effect
Length of ICU stay No effect
Hemodynamics Improved MAP Decreased VP Significant improvement in the treatment group
Other results Decrease in endotoxin and procalcitonin levels Decreased endotoxin levels Decreased endotoxin levels
Safety   Low platelets, two patients requiring transfusion but no bleeding  
  1. EAA endotoxin activity assay, ST standard therapy, MAP mean arterial pressure, VP vasopressors, LPS lipopolysaccharide, HP hemoperfusion